Tag Archives: diagnostics

Rayno Life Science Portfolio Update: BLUD,ILMN, NEOG,SQNM

Immucor (BLUD) stock was up 5.7% to $18.91 on news that the DOJ closed its anti-trust investigation. The stock hit a low in early October when it slashed guidance due to lower utility of blood transfusion services.The Company is  a leader in automated blood transfusion systems but still faces litigation regarding price fixing and regulatory […]

Comments Off Continue Reading →

Successful IPO’s in Genomics Could Ignite Biotech Stocks

The IPO market is setting up for continued investor interest in the biotech sector. Two high profile genomics companies,Complete Genomics and Pacific Biosciences, have filed S-1 Registration Statements with plans to go public in the fourth quarter around the time when market seasonality becomes more bullish. Biotech has been a strong sector  in a choppy […]

Comments Off Continue Reading →

Sequenom (SQNM) Catching Bids at $5.75

Sequenom is finding price support today at $5.75, volume of 4.6M at 1p, after a severe three  day downdraft triggered by their earnings release. Net loss for Q4 was $18.4M on Revenues of $10.8M. Cash position is $42M. Some pundits didn’t like the inability of the Company to give a detailed financial outlook but that […]

Comments Off Continue Reading →

Clinical Diagnostics Part 2: market sector poised for growth

The drive to reduce healthcare costs and perform Comparative Effectiveness Research can get support from next generation diagnostic tests. A recent article by Bill Malone in Clinical Laboratory News, February 2010 Vol.36 No.2, presents an optimistic scenario for the In Vitro Diagnostics (IVD) Market. Referencing a report from the Embargo Group of Austin,Tx, a recent […]

Comments Off Continue Reading →

New Coverage: genomics and diagnostics-Genomic Health(GHDX)

Genomic Health (GHDX) 2/4/10 Molecular Diagnostics and Genomics Public Company- Market Cap $482M Stock Price $16.5-17.5 Summary Genomic Health is a life science Company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions (Personalized Medicine, Pharmacogenomics). In 2004 Genomic Health launched […]

Comments Off Continue Reading →

CompuGen(CGEN) deal sparks small cap biodiscovery stocks

CompuGen, an early stage drug and diagnostic discovery Company announced today a “Discovery on Demand” therapeutic peptide collaboration with Pfizer that focuses on three peptide drugs based upon CompuGen in silico discovery platforms. The predicted molecules will be synthesized and delivered to Pfizer for further development. Pfizer will have the right to exercise options for […]

Comments Off Continue Reading →